Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Hemophilia A Clinical Trial

Official title:

Phase I Study Evaluating Safety and Feasibility of Hematopoietic Stem Cell Gene Transfer That Targets Factor VIII Delivery From Platelets for Patients With Hemophilia A

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03818763
• Other study ID #: PRO00033763
• Status: Recruiting
• Phase: Phase 1
• Start date: April 29, 2020
• Est. completion date: May 1, 2033

Study information

• Verified date: April 2024
• Source: Medical College of Wisconsin
• Contact: Mary Eapen, MD
• Phone: 414-805-0700
• Email: meapen[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase I study. This research study is being conducted to find new ways to treat severe hemophilia A. This study is a gene therapy study. Gene therapy is an experimental way to introduce, into a person's cells, specific genetic material. A gene can be delivered/introduced into a cell using a carrier known as a "vector." In this study, a virus (lentivirus), the "vector", is used to introduce or deliver a gene that creates and stores a protein Factor VIII (FVIII) in your platelets. These platelets are made from stem cells (mother cells for your bone marrow) that are removed from your blood by a procedure called apheresis. This research study will take some of the patient's own stem cells, from the apheresis procedure, and genetically modify them using the vector in order to make them produce FVIII in platelets that arise from the stem cells. They will then give the genetically modified stem cells back to the patient so that they can possibly create platelets that produce and store Factor VIII on their own.

Description:

This is an open label, nonrandomized, single center, phase I cohort study, involving reduced intensity conditioning, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS (MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU) .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: May 1, 2033
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Study population will include: adult males >18 years of age with a diagnosis of severe hemophilia A and currently active or a history of FVIII inhibitors (=0.6 BU). Females will be excluded because hemophilia A is an X-linked disorder that is extremely rare in females.

1. Confirmed diagnosis of severe hemophilia A by undetectable plasma factor VIII:C by a one-stage PTT-based assay and coatest chromogenic factor VIII assay. Subjects with currently active or a history of positive FVIII inhibitor titers (=0.6 BU) irrespective of their titer or current inhibitor status will be included for enrollment.

2. Subject may be prescribed prophylactic therapy with factor VIII bypassing agents or factor VIII mimetics prior to referral for inclusion in the study.

3. Subjects who are treated on demand using factor VIII bypassing agents must have a history of four or more bleeding episodes requiring treatment in the six-month period prior to referral for inclusion in the study.

4. Adequate bone marrow reserve as demonstrated by ANC >1.5/cu.mm; Hemoglobin >9g/dL; Platelets >100,000/microliter.

5. Adequate renal function, defined as creatinine clearance>60 ml/min (Cockroft-Gault formula)

6. Adequate liver function, defined as defined as total bilirubin =1.5 times the upper limit of normal (ULN) (excluding Gilbert's syndrome), both AST and ALT =3 times ULN at the time of screening, and no clinical signs or known laboratory/radiographic evidence consistent with cirrhosis.

7. Subject must sign an informed consent after explanation of the study and having questions answered.

8. Subject must be willing and able to document type of bleeding episodes and treatment in a paper or electronic diary during the study.

9. Subject must be willing to return for regular follow-up visits during the 15-year study.

Exclusion Criteria:

• A potential subject who meets any of the following exclusion criteria is ineligible to participate in the study.

1. Therapy with factor VIII with the intent of immune tolerance induction within 30 days prior to inclusion within the study.

2. Enrollment in another interventional clinical trial within 60 days prior to study inclusion.

3. Medical contraindication to PBSC cytokine mobilization, use of GCSF, PBSC apheresis procedure or conditioning regimen.

4. Medically significant organ dysfunction that would prevent compliance with conditioning or would severely limit the probability of survival based on clinical status.

5. Those with a known co-existing clinically significant thrombophilic disorder, or as determined by the presence of any of the below identified on screening laboratory assessments:

• FV Leiden

• Protein S deficiency

• Protein C deficiency

• Prothrombin mutation (G20210A)

• D-dimer >3 x the upper limit of normal (ULN) at Screening All known patients with the above and any patient with a personal or significant family history of thrombotic events (DVT, PE, arterial clots) as deemed by the principal investigator will be screened for the above disorders.

6. Active invasive malignancy (Non-melanoma skin cancers and carcinoma in situ are not excluded).

7. Known bone marrow disorders or abnormal bone marrow cytogenetics.

8. Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment.

9. Life expectancy severely limited by disease(s) other than hemophilia A.

10. Patients with HIV, hepatitis B, hepatitis C (with an AST/ALT > 3 times the upper limit of normal).

11. Other active infectious disease that is a contraindicat ion for immunosuppressive therapy.

12. Patients who have elective surgery scheduled during the study period.

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Biological:
• Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (=0.6BU). The infusion volume of transduced cells will not exceed 20 ml/kg body weight.

Locations

Country	Name	City	State
United States	Froedtert Hospital and the Medical College of Wisconsin	Milwaukee	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Medical College of Wisconsin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of enrolled participants with adequate gene transduced hematopoietic stem cells for FVIII gene therapy infusion	Assessed by availability of =4x106 transduced clinical grade CD34+PBSC per kg meeting release criteria for infusion; undetectable microbiological contamination and cell viability =70%.	Through study completion, an average of 4 years
Secondary	Incidence of toxicity from gene therapy	Number of events meeting CTCAE criteria grade 3 or 4 toxicity	Within 3 months of gene therapy infusion